Sign in

You're signed outSign in or to get full access.

Alexander Canani

Vice President and Equity Research Analyst at Truist

Alexander Canani is a Vice President and Equity Research Analyst at Truist Securities, specializing in the consumer sector with a focus on retail, apparel, and specialty consumer companies. He covers specific firms including Macy's, Kohl's, VF Corporation, Levi Strauss, and Under Armour, boasting a strong performance track record with a 62% success rate on TipRanks, an average return per rating of 12.5%, and ranking in the top 10% of analysts covering retail stocks. Canani joined Truist in 2022 after previous roles at B. Riley Securities from 2019 to 2022 and earlier at Janney Montgomery Scott starting in 2017, building over seven years of experience in equity research. He holds Series 7, 63, and 86 FINRA licenses, underscoring his professional credentials in securities analysis.

Alexander Canani's questions to ALNYLAM PHARMACEUTICALS (ALNY) leadership

Question · Q4 2025

Alexander Canani inquired about AMVUTTRA's access in community centers, specifically the proportion of the market inaccessible due to cost or stocking hesitancy, and the breakdown of new diagnoses and managed patients in community settings.

Answer

Tolga Tanguler, Chief Commercial Officer, stated that Alnylam is well-positioned from a payer access standpoint, with the large majority of patients having first-line access regardless of location. He highlighted broad and balanced experience, with alternative site of care agreements ensuring 90% of patients can access AMVUTTRA injections within 10 miles of their homes, having reached critical mass in 2025.

Ask follow-up questions

Fintool

Fintool can predict ALNYLAM PHARMACEUTICALS logo ALNY's earnings beat/miss a week before the call